KINDLIA

Welcome to the Brand page for “KINDLIA”, which is offered here for Pharmaceutical preparations used for the treatment of parathyroid, glandular and hormone disorders; pharmaceutical preparations used for the treatment of renal and kidney disorders; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, autoimmune diseases, inflammation, inflammatory diseases and disorders, neurologic diseases and disorders, metabolic diseases and disorders; pharmaceuticals for stimulating the growth of platelets and platelet precursor cells; erythropoiesis stimulating protein; pharmaceuticals for stimulating white blood cell production; pharmaceuticals for modulating the level of calcium in the bloodstream and for the treatment of hyperparathyroidism and hypercalcemia; pharmaceuticals for treating human immune diseases and conditions; pharmaceutical preparations for the treatment of bone disease; and pre-filled syringes containing pharmaceutical preparations for treatment of the aforementioned diseases and disorders and complications associated therewith;.

Its status is currently believed to be active. Its class is unavailable. “KINDLIA” is believed to be currently owned by “AMGEN INC.”